However, the more promising immunotherapy is now programmed death 1 (PD-1) or PD ligand 1 (PD-L1) inhibitors, since the PD1/PD-L1 axis plays a key role in physiological immune homoeostasis and tumor immune evasion. Here, CD274 is linked to neoplasm.